ClinicalTrials.gg
CompletedNCT00844922Updated Dec 31, 2014

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

A Phase 2 interventional study of SCH 900636 and Placebo in Depressive Disorders, Psychotic Disorders and Depression, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-31.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized to Org 34517 (SCH 900636), regardless of dose, were titrated to 900 mg Org 34517. Patients in this trial took their study medication for 2 weeks in order to study the safety and tolerability of Org 34517.

02

Conditions studied

  • Depressive Disorders
  • Psychotic Disorders
  • Depression
03

In context

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

This study's enrollment of 16 is below the median of 88 across 689 interventional studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of previous trial 28130;
  • have a CGI of Severity score of 3 or greater at Day 43 of previous trial 28130 and at Day 1 of current trial 28133, or a lower score when the investigator is of the opinion that further resolution of symptoms is warranted;
  • be on a stable dose of 'usual treatment', which must consist of an antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes.

Exclusion criteria

Exclusion Criteria:

  • had experienced any of the following significant safety outcomes in previous trial 28130:

    • severe breakthrough bleeding;
    • diagnosis of prostatitis;
    • abnormal level of testosterone at Day 15 of previous trial 28130;
    • any adverse event deemed relevant for exclusion in trial 28133 by the investigator.
  • had an abnormal PSA test at Day -7 of previous trial 28133
  • were at significant risk of committing suicide, as indicated by a score greater than 9 on the revised ISST at Day -7 or Day 1;
  • were currently treated with carbamazepine or valproate, midazolam, or clozapine;
  • had been treated with electroconvulsive therapy (ECT) in the current episode;
  • were currently treated with more than one antidepressant, antipsychotic, or mood stabilizer;
  • had 'usual treatment' started or discontinued in the 2 weeks before Day 1;
  • had a 'usual treatment' dose change within one week prior to Day 1;
  • had any clinically unstable or uncontrollable renal, hepatic, respiratory, hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy;
  • had known reactions to antagonists;
  • had any abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or results, or a clinically significant abnormal outcome at the physical examination at Day -7;
  • had a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Day -7;
  • had any untreated or uncompensated clinically significant endocrine disorder;
  • were using hormone replacement therapy at Day -7;
  • required concomitant treatment with corticosteroids (topical use was allowed);
  • women of without adequate
  • women with a positive pregnancy test at Day -7 or 1, or are breast feeding mothers.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Org 34517

    Org 34517 titrated to 900 mg daily for 2 weeks

    Drug: SCH 900636

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the "usual treatment" for psychotic major depression.

    Also known as: Org 34517

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability measures (vital signs, AEs)

    Time frame: 4 weeks

Secondary outcomes

  1. 17-item Hamilton Rating Scale for Depression (HAMD) total score

    Time frame: 4 weeks

  2. proportion of BPRS 30% responders; proportion of subjects with sustained BPRS 30% response

    Time frame: 4 weeks

  3. proportion of HAMD 50% responders; proportion of subjects with sustained HAMD 50% response

    Time frame: 4 weeks

  4. clinical global impression (CGI)

    Time frame: 4 weeks

  5. PANNS total score

    Time frame: 4 weeks

  6. PANSS positive scale score, PANSS negative scale score, PANSS general psychopathology score

    Time frame: 4 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2009
First posted
Feb 16, 2009
Start
Sep 2005
Primary completionActual
Jun 2006
CompletionActual
Jun 2006
Last update
Dec 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00844922
Responsible party
Sponsor
First posted
Feb 16, 2009
Start date
Sep 2005
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Dec 31, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Org-34517

Start the discussion